The present invention is directed to methods for using particles (e.g, microparticulate, nanoparticulate; magnetic, non-magnetic) comprising surfaces comprising capture moieties as described herein, to remove an interference as described herein, or enrich biomarkers, prior to a diagnostic test.

The present disclosure is directed to methods of performing direct affinity-size exclusion chromatography, wherein there is a direct elution of the sample from the affinity chromatography column to the SEC column. The methods described herein allow for rapid and robust purification of target analytes from heterogeneous samples, and mitigate the need for complicated valve switching, buffer exchange, or other sample manipulation.

Systems, methods, and compositions can be used for separating, isolating and/or selecting cells. The methods can utilize beads and/or matrices that bind cells. The beads and/or matrices can be dissolvable. The disclosed systems, methods, and compositions can include magnetic particles and/or buoyant components. The disclosed systems, methods, and compositions can implement size selection.

The present invention aims to provide a fucose-binding protein that shows improved productivity in cases of expression in a host such as Escherichia coli, improved binding affinity to a fucose-containing sugar chain such as a sugar chain containing a structure composed of Fuc1-2Gal1-3GlcNAc and/or Fuc1-2Gal1-3GalNAc, and/or improved thermal stability. The above object is achieved by deleting a plurality of amino acid residues in the C-terminal side of the amino acid sequence of the fucose-binding protein BC2LCN of SEQ ID NO: 1, and, when necessary, substituting the glycine residue at position 36 in SEQ ID NO: 1 with a cysteine residue, substituting the glutamine residue at position 39 in SEQ ID NO: 1 with a leucine residue or methionine residue, substituting the glutamine residue at position 65 in SEQ ID NO: 1 with a leucine residue, substituting the cysteine residue at position 72 in SEQ ID NO: 1 with a glycine residue or alanine residue, substituting the glutamic acid residue at position 81 in SEQ ID NO: 1 with a cysteine residue, glutamine residue, histidine residue, or methionine residue, and/or substituting the glycine residue identified as the residue at position 36 in SEQ ID NO: 1 with a cysteine residue.

The present invention relates to a method for separating and purifying CVB1, and particularly, relates to a method for purifying CVB1 virus by using a heparin affinity medium.